{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HEPATITIS+C",
    "query": {
      "condition": "HEPATITIS C"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 923,
    "total_pages": 93,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HEPATITIS+C&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T22:50:17.444Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05270135",
      "title": "ASAP: Access to Syringes at Pharmacies for the Prevention of Bloodborne Infections Among People Who Inject Drugs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Skin and Soft Tissue Infections",
        "Hiv",
        "Hepatitis C",
        "Bloodstream Infection"
      ],
      "interventions": [
        {
          "name": "ASAP",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Arizona",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2022-12-01",
      "completion_date": "2023-09-30",
      "has_results": false,
      "last_update_posted_date": "2023-12-19",
      "last_synced_at": "2026-06-26T22:50:17.444Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05270135"
    },
    {
      "nct_id": "NCT00395421",
      "title": "Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "NM283 plus Peg-IFNα-2a",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 114,
      "start_date": "2006-10",
      "completion_date": "2008-08",
      "has_results": false,
      "last_update_posted_date": "2010-06-10",
      "last_synced_at": "2026-06-26T22:50:17.444Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • Fairfax, Virginia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00395421"
    },
    {
      "nct_id": "NCT00535847",
      "title": "A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Telaprevir",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Pegylated interferon alfa 2a",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 117,
      "start_date": "2007-10",
      "completion_date": "2010-02",
      "has_results": true,
      "last_update_posted_date": "2014-08-05",
      "last_synced_at": "2026-06-26T22:50:17.444Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 35 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00535847"
    },
    {
      "nct_id": "NCT00381433",
      "title": "Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Encephalitis"
      ],
      "interventions": [
        {
          "name": "AVI-4065 Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sarepta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "MALE",
        "summary": "18 Years to 64 Years · Male only"
      },
      "enrollment_count": 12,
      "start_date": "2006-09",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2009-07-08",
      "last_synced_at": "2026-06-26T22:50:17.444Z",
      "location_count": 1,
      "location_summary": "Tacoma, Washington",
      "locations": [
        {
          "city": "Tacoma",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00381433"
    },
    {
      "nct_id": "NCT03382847",
      "title": "HCV Positive Heart Donors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "Transplant with HCV positive donor, followed by surveillance and treatment of viremia",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 25,
      "start_date": "2018-01-05",
      "completion_date": "2020-05-06",
      "has_results": true,
      "last_update_posted_date": "2021-02-03",
      "last_synced_at": "2026-06-26T22:50:17.444Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03382847"
    },
    {
      "nct_id": "NCT01866930",
      "title": "Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Hepatitis C Infection"
      ],
      "interventions": [
        {
          "name": "Pegylated Interferon Lambda-1a",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Daclatasvir (DCV)",
          "type": "DRUG"
        },
        {
          "name": "Ribasphere (RBV)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 453,
      "start_date": "2013-07-11",
      "completion_date": "2015-08-27",
      "has_results": true,
      "last_update_posted_date": "2023-06-13",
      "last_synced_at": "2026-06-26T22:50:17.444Z",
      "location_count": 13,
      "location_summary": "Rialto, California • San Francisco, California • Aurora, Colorado + 7 more",
      "locations": [
        {
          "city": "Rialto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01866930"
    },
    {
      "nct_id": "NCT03801707",
      "title": "Utilization of Hepatitis C Positive Kidneys in Negative Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Kidney Transplant",
        "Hepatitis C",
        "HCV"
      ],
      "interventions": [
        {
          "name": "Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]",
          "type": "DRUG"
        },
        {
          "name": "Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2019-03-22",
      "completion_date": "2021-04-30",
      "has_results": true,
      "last_update_posted_date": "2023-09-13",
      "last_synced_at": "2026-06-26T22:50:17.444Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03801707"
    },
    {
      "nct_id": "NCT00008463",
      "title": "A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections",
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Interferon alfa-2a",
          "type": "DRUG"
        },
        {
          "name": "Peginterferon alfa-2a",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 132,
      "start_date": "2000-11",
      "completion_date": "2006-08",
      "has_results": false,
      "last_update_posted_date": "2021-11-01",
      "last_synced_at": "2026-06-26T22:50:17.444Z",
      "location_count": 24,
      "location_summary": "San Diego, California • San Francisco, California • Aurora, Colorado + 12 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00008463"
    },
    {
      "nct_id": "NCT04198584",
      "title": "Study of Telemedicine Stress Management and Lifestyle Group Intervention for HCV Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "VC-CBCS",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2020-04-10",
      "completion_date": "2021-02-24",
      "has_results": true,
      "last_update_posted_date": "2022-10-24",
      "last_synced_at": "2026-06-26T22:50:17.444Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04198584"
    },
    {
      "nct_id": "NCT02588287",
      "title": "Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hepatitis C and HIV Coinfection"
      ],
      "interventions": [
        {
          "name": "Blood draws for tenofovir PK, renal function",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 14,
      "start_date": "2015-11",
      "completion_date": "2016-09",
      "has_results": false,
      "last_update_posted_date": "2021-08-11",
      "last_synced_at": "2026-06-26T22:50:17.444Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02588287"
    }
  ]
}